Skip to main content

2025 IDWeek Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Session Icons

Live Streamed

On Demand

144 Views

Discussion + Q&A

A6. New drug development (formerly L3)

Poster Session: New Drug Development

(P-1166) Obeldesivir clinical dose projection for Marburg virus infection post-exposure prophylaxis

Tuesday, October 21, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

Jack Chang, Jr., PharmD, MSCI

Clinical Pharmacologist
Gilead Sciences, Inc.
Foster City, CA, United States

Co-Author(s)

ES

Eric Salgado, PhD

Gilead Sciences, Inc.
Foster City, California, United States
DB

Darius Babusis, BA

Gilead Sciences, Inc.
Foster City, California, United States
MV

Meghan Vermillion, DVM, PhD

Lovelace Biomedical Research Institute
Albuquerque, New Mexico, United States
SD

Santosh Davies, MD

Gilead Sciences, Inc.
Foster City, California, United States
RB

Roy Bannister, PhD

Gilead Sciences, Inc.
Foster City, California, United States
YM

Yoshihiko Murata, MD, PhD

Gilead Sciences, Inc.
Foster City, California, United States
LC

Luzelena Caro, PhD

Gilead Sciences, Inc.
Foster City, California, United States